307 related articles for article (PubMed ID: 22278840)
21. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
22. Post kala-azar dermal leishmaniasis: A threat to elimination program.
Gedda MR; Singh B; Kumar D; Singh AK; Madhukar P; Upadhyay S; Singh OP; Sundar S
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008221. PubMed ID: 32614818
[TBL] [Abstract][Full Text] [Related]
23. Post-kala-azar dermal leishmaniasis mimicking leprosy: experience with 4 patients, with some unusual features in 1.
Dhar S; Kaur I; Dawn G; Sehgal S; Kumar B
Lepr Rev; 1995 Sep; 66(3):250-6. PubMed ID: 7500822
[TBL] [Abstract][Full Text] [Related]
24. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
25. Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012.
Desjeux P; Ghosh RS; Dhalaria P; Strub-Wourgaft N; Zijlstra EE
Parasit Vectors; 2013 Jul; 6():196. PubMed ID: 23819611
[TBL] [Abstract][Full Text] [Related]
26. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
Saha S; Mazumdar T; Anam K; Ravindran R; Bairagi B; Saha B; Goswami R; Pramanik N; Guha SK; Kar S; Banerjee D; Ali N
J Clin Microbiol; 2005 Mar; 43(3):1269-77. PubMed ID: 15750095
[TBL] [Abstract][Full Text] [Related]
27. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
[TBL] [Abstract][Full Text] [Related]
28. Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.
Dey A; Singh S
Infect Genet Evol; 2007 Mar; 7(2):219-22. PubMed ID: 17027344
[TBL] [Abstract][Full Text] [Related]
29. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
30. Atypical presentation of post-kala-azar dermal leishmaniasis.
Islam QT; Basher A
Lancet Infect Dis; 2017 Nov; 17(11):1218. PubMed ID: 29115271
[No Abstract] [Full Text] [Related]
31. Real-Time Fluorimetry Loop-Mediated Isothermal Amplification for Diagnosis of Leishmaniasis and as a Tool for Assessment of Cure for Post-Kala-Azar Dermal Leishmaniasis.
Dixit KK; Ramesh V; Gupta R; Negi NS; Singh R; Salotra P
Am J Trop Med Hyg; 2021 Apr; 104(6):2097-2107. PubMed ID: 33872204
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
33. Leishmaniasis chemotherapy--challenges and opportunities.
Croft SL; Olliaro P
Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.
Kaushal H; Bras-Gonçalves R; Avishek K; Kumar Deep D; Petitdidier E; Lemesre JL; Papierok G; Kumar S; Ramesh V; Salotra P
Clin Exp Immunol; 2016 Jul; 185(1):50-60. PubMed ID: 26948150
[TBL] [Abstract][Full Text] [Related]
35. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
[TBL] [Abstract][Full Text] [Related]
36. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
37. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
38. An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.
Routaray CB; Kumar A; Sundar S; Sathe G; Pawar H; Pai K
Acta Parasitol; 2022 Jun; 67(2):687-696. PubMed ID: 35020128
[TBL] [Abstract][Full Text] [Related]
39. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
Singh S ; Kumar J; Singh R; Dwivedi SN
Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
